Muscle WeaknessNCT06998134
Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
An observational study of Muscle Weakness and Problems Moving Their Arms and Legs, run by National Institutes of Health Clinical Center (CC) at 1 site in United States.
Trial summary
People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. Read more about this study
- Who is it for?
- Ages 5 to 25 years
- Conditions the study is for
- Muscle Weakness, Problems Moving Their Arms and Legs
- What is being tested?
- Extension assist knee ankle foot orthosis (EA-KAFO)
- Type of treatment
- Medical device
- How many people
- 23 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jun 2026to 18 Aug 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Patient age 5-25 cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs
Who may be able to join
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.
- Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
- Age 5 to 25 years old. Importantly, we included young adults (18-25 years old) because longterm outcomes for adults with cerebral palsy include loss of ambulatory ability. While studies of conventional gait training in this population have been conducted, use of exoskeletons in this population is very limited. Given the potential benefit of exoskeletons to reduce knee extension deficiency, it is important to determine whether novel controllers we develop are also tolerated and effective in this age group.
- Either has a gait pathology arising from a diagnosis of CP, MD, SB, or iSCI or has no gait pathology.
- Knee joint range of motion of at least 25 degrees in the sagittal plane (knee extension/flexion) assessed with the hip extended in a supine position. Hamstring contracture as assessed by the straight leg raising test does not limit ability to participate in the study.
- Ankle joint range of motion of at least 15 degrees in the sagittal plane (dorsi-plantarflexion) with the foot in neutral alignment.
- Able to walk at least 10 feet without stopping with or without a walking aid.
Who cannot join
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Any neurological, musculoskeletal, or cardiorespiratory injury, health condition, or diagnosis other than CP, MD, SB, or iSCI that would affect the ability to walk as directed with the robotic exoskeleton.
- A history of uncontrolled seizures in the past year.
- Pregnancy based on self-reporting. We excluded pregnancy due to confounding factors of pregnancy on gait.
- Adult unable to consent for themselves at screening visit.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
NIH Clinical Center Office of Patient Recruitment (OPR), 800-411-1222 ext. TTY dial 711, ccopr@nih.gov
About this study
Official title: Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults: Exploratory Observational Analysis of Novel Robotic Control Strategies
People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating new ways the exoskeleton can be used in multiple settings while performing different walking or movement tasks, which we call ubiquitous use. For example, we will ask you to walk on a treadmill at different speeds, walk up and down a ramp, or walk through an obstacle course. Optionally, the exoskeletons may also use functional electrical stimulation (FES), a system that sends electrical pulses to the muscle to help it move the limb.
Read the detailed description
STUDY DESCRIPTION:
The following exploratory observational study is designed to create a framework that permits rapid development, piloting, and acute evaluation of pediatric exoskeleton control paradigms for daily, ubiquitous use across multiple settings. Most existing evaluations of pediatric exoskeleton control modes are limited to a flat walking task.The novelty of this study design is the translation of control modes to different functional tasks and comparisons between fixed and adaptive parameters across the tasks. Across all participants, three main control modes will be tested: assist, resist, and interleaved (alternating assist and resist). Control parameters will either be fixed for all tasks conducted or may adapt based on the motions of a given activity. Following informed consent and assent, screening, and calibration of control parameters, an acclimation period to the exoskeleton and control modes will occur. Each control mode will be tested across ubiquitous activities of daily living and outcomes will be compared to baseline (without wearing the exoskeleton). Our central hypothesis is that existing control paradigms that have been previously validated in walking can be successfully translated to improve knee extension deficiency and/or knee extensor muscle activity in multiple different functional mobility tasks.
OBJECTIVES:
- Primary Objectives: 1) To evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks and 2) Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.
- Secondary objectives: 1) Measuring functional performance of tasks conducted with each control paradigm and 2) Characterizing muscle activation of knee extensors during each task.
ENDPOINTS:
Primary Endpoints:
- To evaluate knee extension deficiency, we will use 1) Peak knee extension and 2) Range of knee angle excursion (difference between maximum extension and flexion). These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
- To characterize controller behavior and performance, we will use the root mean square error (RMSE) between the exoskeleton knee torque profile delivered in real-time and the ideal knee torque profile computed from the user s kinematics. This endpoint will be measured during each assessment visit.
Secondary Endpoints:
-To evaluate functional performance in:
- self-selected speed treadmill walking, overground walking, stairs, and ramps, we will use gait speed, stride length, and number of gait cycles.
- variable-speed treadmill walking, we will use cadence, stride length, and number of gait cycles.
- Timed Up and Go and stairs, we will use the duration of the task.
- the Standardized Walking Obstacle Course, we will use the time to traverse the environment.
- the 2-Minute Walk Test, we will use the distance covered during the task.
- the squat test, we will use the number of squats completed.
These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.
To characterize muscle activation, we will use 1) peak knee extensor activation during the task and 2) area under the normalized EMG curve over the duration of the task. These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.
- Being tested
- Extension assist knee ankle foot orthosis (EA-KAFO)
- Keywords
- Cerebral Palsy (CP), muscular dystrophy (MD), Spina Bifida, incomplete spinal cord injury
- Medical subject headings
- Muscle Weakness, Cerebral Palsy, Muscular Dystrophies, Spinal Dysraphism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extension assist knee ankle foot orthosis (EA-KAFO)Device
A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion).
| Study group | Role | What they receive |
|---|---|---|
| Cerebral Palsy (CP) | Male and female age 5-25 Receives: Device: Extension assist knee ankle foot orthosis (EA-KAFO) | |
| Incomplete Spinal Cord Injury | Male and female age 5-25 Receives: Device: Extension assist knee ankle foot orthosis (EA-KAFO) | |
| Muscular Dystrophy | Male and female age 5-25 Receives: Device: Extension assist knee ankle foot orthosis (EA-KAFO) | |
| Spina Bifida | Male and female age 5-25 Receives: Device: Extension assist knee ankle foot orthosis (EA-KAFO) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks.
To evaluate knee extension deficiency, we will use:1) Peak knee extension and2) Range of knee angle excursion (difference between maximum extension and flexion).These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
Measured: 4 months
Secondary outcomes (1)
Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.
To ensure controllers are appropriately developed for ubiquitous use, it is vital to determine whether their intended behavior is consistent with design specifications across tasks.
Measured: 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2025
- Study start23 Jun 2026
- Primary completion18 Aug 2028 (estimated)
- Study completion18 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Muscle WeaknessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 23 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Thomas C Bulea, Ph.D., Principal investigator, National Institutes of Health Clinical Center (CC)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06998134
- Sponsor's protocol ID
- 10002278
- Other IDs
- 002278-CC
- Status last verified
- 17 Jul 2026
- First submitted
- 30 May 2025
- Last updated
- 23 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37. doi: 10.1212/01.wnl.0000252807.38124.a3.
PubMed 17261678Emery AE. The muscular dystrophies. Lancet. 2002 Feb 23;359(9307):687-95. doi: 10.1016/S0140-6736(02)07815-7.
PubMed 11879882Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet. 2004 Nov 20-26;364(9448):1885-95. doi: 10.1016/S0140-6736(04)17445-X.
PubMed 15555669McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002 Feb 2;359(9304):417-25. doi: 10.1016/S0140-6736(02)07603-1.
PubMed 11844532Damiano DL, Abel MF. Relation of gait analysis to gross motor function in cerebral palsy. Dev Med Child Neurol. 1996 May;38(5):389-96. doi: 10.1111/j.1469-8749.1996.tb15097.x.
PubMed 8698147
Study at a glance
From the registry record, last updated by the sponsor on 23 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults: Exploratory Observational Analysis of Novel Robotic Control Strategies
- ClinicalTrials.gov ID
- NCT06998134
- Acronym / sponsor ID
- 10002278
- Keywords
- Cerebral Palsy (CP), muscular dystrophy (MD), Spina Bifida, incomplete spinal cord injury
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 23 participants (estimated)
- Lead sponsor
- National Institutes of Health Clinical Center (CC)US National Institutes of Health
- Study start
- 23 Jun 2026 (actual)
- Primary completion
- 18 Aug 2028 (estimated)
- Study completion
- 18 Aug 2028 (estimated)
- First posted
- 31 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
People with cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs. The NIH designed a new brace device, called an exoskeleton, that is worn on the legs and helps people walk. This study is investigating new ways the exoskeleton can be used in multiple settings while performing different walking or movement tasks, which we call ubiquitous use. For example, we will ask you to walk on a treadmill at different speeds, walk up and down a ramp, or walk through an obstacle course. Optionally, the exoskeletons may also use functional electrical stimulation (FES), a system that sends electrical pulses to the muscle to help it move the limb.
Detailed description
STUDY DESCRIPTION:
The following exploratory observational study is designed to create a framework that permits rapid development, piloting, and acute evaluation of pediatric exoskeleton control paradigms for daily, ubiquitous use across multiple settings. Most existing evaluations of pediatric exoskeleton control modes are limited to a flat walking task.The novelty of this study design is the translation of control modes to different functional tasks and comparisons between fixed and adaptive parameters across the tasks. Across all participants, three main control modes will be tested: assist, resist, and interleaved (alternating assist and resist). Control parameters will either be fixed for all tasks conducted or may adapt based on the motions of a given activity. Following informed consent and assent, screening, and calibration of control parameters, an acclimation period to the exoskeleton and control modes will occur. Each control mode will be tested across ubiquitous activities of daily living and outcomes will be compared to baseline (without wearing the exoskeleton). Our central hypothesis is that existing control paradigms that have been previously validated in walking can be successfully translated to improve knee extension deficiency and/or knee extensor muscle activity in multiple different functional mobility tasks.
OBJECTIVES:
- Primary Objectives: 1) To evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks and 2) Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.
- Secondary objectives: 1) Measuring functional performance of tasks conducted with each control paradigm and 2) Characterizing muscle activation of knee extensors during each task.
ENDPOINTS:
Primary Endpoints:
- To evaluate knee extension deficiency, we will use 1) Peak knee extension and 2) Range of knee angle excursion (difference between maximum extension and flexion). These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
- To characterize controller behavior and performance, we will use the root mean square error (RMSE) between the exoskeleton knee torque profile delivered in real-time and the ideal knee torque profile computed from the user s kinematics. This endpoint will be measured during each assessment visit.
Secondary Endpoints:
-To evaluate functional performance in:
- self-selected speed treadmill walking, overground walking, stairs, and ramps, we will use gait speed, stride length, and number of gait cycles.
- variable-speed treadmill walking, we will use cadence, stride length, and number of gait cycles.
- Timed Up and Go and stairs, we will use the duration of the task.
- the Standardized Walking Obstacle Course, we will use the time to traverse the environment.
- the 2-Minute Walk Test, we will use the distance covered during the task.
- the squat test, we will use the number of squats completed.
These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.
To characterize muscle activation, we will use 1) peak knee extensor activation during the task and 2) area under the normalized EMG curve over the duration of the task. These endpoints will be measured and compared between each control strategy used within each task during the assessment visit.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cerebral Palsy (CP) | – | Device: Extension assist knee ankle foot orthosis (EA-KAFO)Male and female age 5-25 |
| Incomplete Spinal Cord Injury | – | Device: Extension assist knee ankle foot orthosis (EA-KAFO)Male and female age 5-25 |
| Muscular Dystrophy | – | Device: Extension assist knee ankle foot orthosis (EA-KAFO)Male and female age 5-25 |
| Spina Bifida | – | Device: Extension assist knee ankle foot orthosis (EA-KAFO)Male and female age 5-25 |
Who may qualify
- Ages
- 5 to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Patient age 5-25 cerebral palsy (CP), muscular dystrophy (MD), spina bifida, or spinal cord injury often have muscle weakness, and problems moving their arms and legs
Key inclusion criteria (8 listed)
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision of signed and dated separate informed consent and assent forms for screening purposes. Upon inclusion in the protocol, provision of signed and dated informed consent and assent forms to begin participation in the study will be necessary.
- Stated willingness to comply with all study procedures and availability for the duration of the study, or alternatively, ability to do so based on parent report and physician observation during history and physical examination.
- Age 5 to 25 years old. Importantly, we included young adults (18-25 years old) because longterm outcomes for adults with cerebral palsy include loss of ambulatory ability. While studies of conventional gait training in this population have been conducted, use of exoskeletons in this population is very limited. Given the potential benefit of exoskeletons to reduce knee extension deficiency, it is important to determine whether novel controllers we develop are also tolerated and effective in this age group.
- Either has a gait pathology arising from a diagnosis of CP, MD, SB, or iSCI or has no gait pathology.
Key exclusion criteria (5 listed)
- An individual who meets any of the following criteria will be excluded from participation in this study:
- Any neurological, musculoskeletal, or cardiorespiratory injury, health condition, or diagnosis other than CP, MD, SB, or iSCI that would affect the ability to walk as directed with the robotic exoskeleton.
- A history of uncontrolled seizures in the past year.
- Pregnancy based on self-reporting. We excluded pregnancy due to confounding factors of pregnancy on gait.
- Adult unable to consent for themselves at screening visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extension assist knee ankle foot orthosis (EA-KAFO)A lower limb exoskeleton that has one actuated degree of freedom at the knee (flexion/extension) and a passive degree of freedom at the ankle (plantar/dorsiflexion). | Device | Cerebral Palsy (CP), Incomplete Spinal Cord Injury, Muscular Dystrophy, Spina Bifida |
Primary outcome
Evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks.
Time frame: 4 months
To evaluate knee extension deficiency, we will use:1) Peak knee extension and2) Range of knee angle excursion (difference between maximum extension and flexion).These endpoints will be measured and compared between each control strategy within each task during the assessment visit.
1 secondary outcome
Assess whether controller behavior and performance align with the intent of its prescribed design consistently across tasks.
Time frame: 4 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jul 2026.
- Background: PubMed 17261678Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the "common" neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37. doi: 10.1212/01.wnl.0000252807.38124.a3.
- Background: PubMed 11879882Emery AE. The muscular dystrophies. Lancet. 2002 Feb 23;359(9307):687-95. doi: 10.1016/S0140-6736(02)07815-7.
- Background: PubMed 15555669Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. Lancet. 2004 Nov 20-26;364(9448):1885-95. doi: 10.1016/S0140-6736(04)17445-X.
- Background: PubMed 11844532McDonald JW, Sadowsky C. Spinal-cord injury. Lancet. 2002 Feb 2;359(9304):417-25. doi: 10.1016/S0140-6736(02)07603-1.
- Background: PubMed 8698147Damiano DL, Abel MF. Relation of gait analysis to gross motor function in cerebral palsy. Dev Med Child Neurol. 1996 May;38(5):389-96. doi: 10.1111/j.1469-8749.1996.tb15097.x.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Muscle Weakness
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Active, not recruitingPhase 1
E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults
Rotator Cuff Tears, Muscle Atrophy or Weakness
Recruiting
Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients
Mobility Limitation, Frailty
Not yet recruiting
Virtual Reality Training Dose for Arm Recovery After Stroke: Clinical and Blood Biomarker Responses
Stroke, Upper Extremity Paresis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas C Bulea, Ph.D. principal investigator
National Institutes of Health Clinical Center (CC)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Muscle Weakness and Problems Moving Their Arms and Legs, run by National Institutes of Health Clinical Center (CC) at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jesse H Matsubara ((301) 451-7530, jesse.matsubara@nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate acute biomechanical and neuromuscular effects of pediatric exoskeleton control paradigms on knee extension deficiency across ubiquitous tasks. (time frame: 4 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06998134, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jul 2026.